Medical Cannabis Studies

• View All (505)

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid (2008)

Cannabidiol has the ability to kill glioma cells both in vitro and in vivo, independently of the stimulation of cannabinoid receptors. In this study performed in mice, the in vivo exposure of the tumor tissues with cannabidiol demonstrated a significant decrease in the activity and content of 5-lipoxygenase (LOX, 40%) and its final pipeline, leukotriene B4 (25 %). It is demonstrated in this study that cannabidiol exerts its antitumor effects through the modulation of the LOX pathway and the endocannabinoid system. This suggests a possible interaction of these routes in the control of tumor growth. View study
9-Tetrahydrocannabinolic acid synthase production in Pichia pastoris enables chemical synthesis of cannabinoids (Page not found)

View study
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells (2006)

Cannabidiol hydroxyquinone (HU-331) has a great potential to become an antiangiogenic and anticancer drug. This study demonstrated that HU-331 was able to significantly inhibit angiogenesis at very low concentrations, in addition to significantly decreasing the total area occupied by the vessels in the treated tumors. View study
A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma (2011)

Gliobastoma multiforme is highly resistant to current cancer treatments. However, the combined administration of D9 tetrahydrocannabinol and temozolomide exerts a strong antitumor action on glioma xenografts, suggesting that it could be exploited therapeutically for the treatment of gliobastoma multiforme. View study
A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology (2008)

THC competitively inhibits the enzyme acetylcholinesterase (AChE) and prevents the aggregation of amyloid ? peptide induced by AChE (A?), the key pathological marker of Alzheimer’s disease. View study
A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes. (2018)

In Canada, the Cannabis Access Regulation for Medical Purposes (ACMPR) has granted practicing nurses (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This national study was focused to assess NPs�knowledge and practice gaps related to CTP to inform the development of future education resources that increase NPs’ clinical competence and improve patient care related to medical cannabis. View study
A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers (2013)

The objective of this study was to evaluate the possible drug interactions of the oromucosal aerosol of THC and CBD Sativex�, nabiximols in combination with the cytochrome P450 (CYP450) inducer (rifampin) or inhibitors (ketoconazole or omeprazole). Based on our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes in the PK parameters of the THC / CBD spray, but potential effects should be considered when co-administered THC / CBD with compounds that share the CYP3A4 pathway like rifampicin or ketoconazole. View study
A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme (2006)

Due to its ability to inhibit tumor growth in animals, THC and other cannabinoids have been suggested as antitumor drugs. This is the first clinical study to test the application of THC in human patients with recurrent glioblastoma multiforme. The results demonstrate the safety profile of THC and its action on tumor cells, which establishes the basis for future trials. View study
A prospective observational study of problematic oral cannabinoid use. (2017)

The present study focused on two objectives. The first objective of this study was to examine the incidence of problematic use of prescription cannabinoids (PPCBU) over a period of 12 months among patients who started treatment with cannabinoids. The second objective was to examine the factors associated with PPCBU. View study
A Review of Molecular Pharmacology (2001)

In this review the effects of THC and gamma-linolenic acid (GLA, in hemp seed oil) on the metabolism of eicosanoids are analyzed and THC is proposed to act as a selective inhibitor of cyclooxygenase-2 (COX) -2). View study
A selective review of medical cannabis in cancer pain managment. (2017)

Insufficient management of chronic and neuropathic pain associated with cancer adversely affects the patient’s quality of life. The objective of this review was to present a selection of representative clinical studies, which evaluated the efficacy of cannabinoid-based treatments containing tetrahydrocannabinol (THC) and cannabidiol (CBD) to reduce pain associated with cancer. View study
A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol (2006)

The combination of tetrahydrocannabinol and cannabidiol increases clinical efficacy in the treatment of spasticity, central pain, lower urinary tract symptoms in multiple sclerosis, sleep disorders, peripheral neuropathic pain, avulsion symptoms of the branchial plexus, arthritis rheumatoid pain and intractable cancer, in addition to reducing the occurrence of adverse effects. View study